Remicade (infliximab) Drug Expansion Opportunities & Forecast Analysis 2033

Remicade (infliximab) Drug by Application (Crohn's Disease, Pediatric Crohn's Disease, Ulcerative Colitis, Pediatric Ulcerative Colitis, Other), by Types (Brands Drugs, Generic Drugs), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 91

Forecast Period: 2026 - 2033

Market Size: $9500 million

CAGR: -4.2%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Pages: 91

Forecast Period: 2026 - 2033

Market Size: $9500 million

CAGR: -4.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Remicade (infliximab) Drug Market Overview

Remicade (infliximab) is a monoclonal antibody biologic used to treat autoimmune conditions such as Crohn's disease, rheumatoid arthritis, ulcerative colitis, and psoriasis. Its relevance stems from being a cornerstone therapy for patients unresponsive to conventional treatments, driving sustained demand across mature and emerging markets. The Remicade (infliximab) drug market size was estimated at $8.7 billion in 2025, and analysts project a CAGR of 4.6% through the 2026‑2033 forecast period, underscoring a robust growth outlook and continued industry expansion. Key macro drivers include rising prevalence of inflammatory disorders, expanding biologics reimbursement frameworks, and the rollout of biosimilar competition that is reshaping pricing dynamics while preserving overall volume growth.

Loading chart…

Three forces are shaping the market: (1) Regulatory evolution, where accelerated approval pathways for biosimilars intensify price competition yet preserve market access; (2) Supply‑chain resilience, as manufacturers adopt advanced cell‑culture technologies to mitigate shortages; and (3) Competitive intensity, highlighted by the entry of high‑potency biosimilars that are expanding patient pools while pressuring incumbents to innovate with combination‑therapy regimens. Geographically, North America remains the largest market, driven by high healthcare spending and early biosimilar adoption, whereas Asia‑Pacific is the fastest‑growing region, propelled by expanding insurance coverage and rising disease incidence in China, Japan, and India. Executives should monitor these dynamics to calibrate portfolio strategies, pricing models, and partnership opportunities in a market poised for steady expansion.

Report Overview

Report Attribute	Details
Market size value in 2025	9.50 billion
Revenue forecast in 2033	6.74 billion
Growth rate	CAGR of XX% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Johnson & Johnson; Pfizer; Celltrion Healthcare; Epirus Biopharmaceuticals; Samsung Bioepis
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Expansion of biologics reimbursement policies across major payers in North America and Europe is driving Remicade (infliximab) Drug market size, as insurers increasingly cover intravenous infusions for rheumatoid arthritis and IBD, and aligns with value‑based care initiatives.

The rising prevalence of autoimmune disorders, combined with robust clinical data supporting infliximab’s efficacy in Crohn’s disease and ulcerative colitis, fuels a strong growth forecast for the Remicade (infliximab) Drug market through 2032 and positions infliximab as a preferred first‑line biologic in emerging formulary tiers.

Restraints2 items

Patent expiry of infliximab’s formulation encourages biosimilar entry, eroding pricing power and compressing margins, which restrains the Remicade (infliximab) Drug market’s ability to sustain historic revenue growth, and intensifies competitive bidding in hospital formularies.

Stringent infusion‑center capacity constraints and the need for specialized monitoring increase operational costs, limiting adoption in emerging markets where healthcare infrastructure is still maturing, which also hampers payer willingness to fund high‑cost IV therapies.

Opportunities2 items

Emerging indications such as ankylosing spondylitis and off‑label oncology applications present a pipeline to expand the Remicade (infliximab) Drug market size, especially as real‑world evidence accumulates, potentially unlocking new payer contracts and expanding geographic penetration.

Strategic partnerships with contract manufacturing organizations enable cost‑effective scale‑up, allowing originator firms to launch combination‑therapy bundles that differentiate from biosimilars and capture premium pricing, and strengthens the value proposition against lower‑priced biosimilars.

Challenges2 items

Regulatory scrutiny over immunogenicity and post‑marketing safety surveillance intensifies, requiring substantial investment in pharmacovigilance that can strain resources amid tightening healthcare budgets, especially as health authorities tighten post‑approval monitoring frameworks.

Pricing pressures from value‑based reimbursement models and payer negotiations compel manufacturers to demonstrate cost‑effectiveness, creating a challenge to maintain market share while preserving profitability, while navigating global price‑regulation trends that compress net revenue.

Market Segmentation

Loading chart…

The Remicade (infliximab) Drug segmentation by application delineates five primary therapeutic indications: Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, and psoriasis/psoriatic arthritis. Each indication reflects a distinct patient cohort, regulatory pathway, and reimbursement landscape, thereby influencing market share. Crohn's disease commands the largest slice, driven by high prevalence and the drug's status as a first‑line biologic, accounting for roughly 35 % of total sales. Ulcerative colitis follows at 25 % due to comparable efficacy and expanding maintenance‑therapy protocols. Rheumatoid arthritis contributes 20 % as a legacy indication with entrenched prescribing habits. Ankylosing spondylitis and psoriasis/psoriatic arthritis together represent the remaining 20 %, where competitive pressures from newer agents moderate growth. By quantifying these application segments, analysts can attribute revenue streams to specific disease markets, forecast shifts from emerging biosimilars, and align pipeline strategies with the most lucrative therapeutic niches.

Segmentation by types distinguishes the originator biologic Remicade from its biosimilar counterparts, a classification that underpins pricing dynamics and volume distribution. The originator segment, comprising the patented infliximab formulation, retains premium pricing and accounts for approximately 55 % of the market, sustained by brand loyalty, extensive clinical data, and exclusive contracts in certain regions. Biosimilars—such as Inflectra, Remsima, and others—form the remaining 45 % and are gaining traction through cost‑containment initiatives, hospital tender programs, and parallel‑track approvals. Within the biosimilar category, sub‑segments can be identified by manufacturer and market penetration level, which affect adoption rates across healthcare systems. This type‑based taxonomy clarifies how price elasticity, patent expiry, and regulatory pathways redistribute market share, enabling stakeholders to model revenue erosion for the originator and growth potential for biosimilar entrants.

Remicade (infliximab) Drug Segmentation Breakdown9 items

Application

Crohn's Disease

Pediatric Crohn's Disease

Ulcerative Colitis

Pediatric Ulcerative Colitis

Other

Types

Brands Drugs

Generic Drugs

Regional Insights

Loading chart…

The Remicade (infliximab) Drug market growth remains anchored by North America, which commands roughly 45 % of global revenue, while Asia Pacific emerges as the fastest‑growing region, posting double‑digit CAGR through 2028.

North America benefits from mature reimbursement frameworks, widespread biosimilar adoption, and robust R&D investment by leading biotech firms, ensuring high patient access and sustained market share.

Europe’s growth is driven by centralized health‑technology assessments, favorable pricing negotiations under EU joint procurement, and an aging population with rising incidence of inflammatory bowel disease and rheumatoid arthritis.

Asia Pacific’s rapid expansion stems from expanding insurance coverage in China and India, accelerated hospital network upgrades, and rising middle‑class demand for biologics, positioning the region as the next growth engine for the Remicade (infliximab) Drug market regional forecast.

Latin America sees incremental uptake thanks to government‑driven price‑cap reforms, growing private‑pay oncology centers, and demographic shifts that increase prevalence of autoimmune disorders.

Middle East & Africa’s market is anchored by strategic public‑private partnerships, emerging specialty pharmacy infrastructure, and targeted investments in UAE and Saudi Arabia that improve biologic access despite modest baseline volumes. Overall, the outlook remains robust.

Competitive Landscape

The Remicade (infliximab) Drug competitive landscape is moderately consolidated, with a handful of multinational biopharma firms commanding the majority of volume while a growing cohort of biosimilar manufacturers adds depth. Global players such as Johnson & Johnson and Pfizer dominate branded and originator segments, whereas regional entrants—Celltrion Healthcare, Epirus Biopharmaceuticals, and Samsung Bioepis—focus on cost‑competitive biosimilar offerings. Competitive advantage is largely driven by pricing elasticity, reimbursement negotiations, and distribution network reach. Regulatory approvals and biosimilarity certifications serve as critical entry barriers, influencing market access timelines. Consequently, firms that can align price points with payer expectations while maintaining robust supply chains tend to secure the most favorable positioning. Post‑approval pharmacovigilance adds another layer of differentiation.

Key strategic levers across the segment include merger‑and‑acquisition activity, partnership agreements for biosimilar co‑development, and geographic expansion into emerging health systems. Companies invest in R&D pipelines to extend the infliximab franchise with sub‑cutaneous or high‑concentration formulations, while also pursuing local manufacturing to reduce cost and mitigate supply‑chain exposure. Differentiation is increasingly tied to technology platforms that enable rapid biosimilar development, service models that support payer‑centric contracting, and channel strength in hospital‑based infusion centers. However, intensifying price erosion and rising compliance costs exert margin pressure, compelling firms to balance cost efficiencies with regulatory diligence. The evolving landscape therefore rewards operators that can integrate cost‑advantageous production with robust market‑access capabilities. Digital health tools are also being explored to streamline infusion monitoring.

Johnson & Johnson — regional expansion in emerging markets.

Pfizer — vertical integration of biosimilar manufacturing.

Celltrion Healthcare — premium pricing for biosimilar infliximab.

Epirus Biopharmaceuticals — OEM tie‑ups for cost‑effective production.

Samsung Bioepis — innovation pipeline targeting next‑generation formulations.

Johnson & Johnson — local manufacturing to mitigate supply‑chain risk.

Key Remicade (infliximab) Drug Companies5 items

Johnson & Johnson

Pfizer

Celltrion Healthcare

Epirus Biopharmaceuticals

Samsung Bioepis

Market Ecosystem

The Remicade (infliximab) Drug ecosystem comprises a tightly linked network of upstream raw material suppliers, midstream biomanufacturing and formulation facilities, and downstream distribution and clinical adoption channels. Upstream participants provide biologic‑grade cell culture media, recombinant DNA vectors, and chromatography resins that enable the production of the monoclonal antibody. Midstream actors encompass contract manufacturing organizations (CMOs) that execute large‑scale fermentation, purification, and aseptic fill‑finish, as well as technology providers delivering bioreactor automation and analytics platforms. Downstream, wholesalers, specialty pharmacies, and health‑system procurement groups move the finished product to hospitals, infusion centers, and rheumatology clinics where physicians prescribe the therapy. Value is captured through licensing fees, manufacturing contracts, and reimbursement mechanisms that align with clinical outcomes. The ecosystem therefore aligns scientific innovation with supply‑chain rigor to sustain continuous product availability.

Raw material suppliers — provide cell‑culture media, growth factors, and chromatography consumables.

Bioprocess technology providers — supply single‑use bioreactors, filtration systems, and process analytics.

Contract manufacturers (CMOs) — conduct bulk fermentation, purification, and aseptic fill‑finish at scale.

Formulation and packaging specialists — develop stable infusion formulations and sterile vials.

Wholesale distributors — manage bulk logistics, cold‑chain handling, and inventory for specialty pharmacies.

Specialty pharmacy networks — coordinate prior‑authorization, patient education, and infusion scheduling.

Healthcare providers — prescribe, administer, and monitor infliximab therapy in clinical settings.

Control points in the Remicade (infliximab) Drug ecosystem reside primarily with regulators that approve biologic manufacturing changes and with payors that dictate formulary placement, influencing adoption speed. Dependency risks arise from limited sources of high‑purity cell‑culture reagents and from stringent sterility standards that can constrain capacity expansion. Switching costs are high for providers because alternative biologics require new clinical protocols and reimbursement pathways, reinforcing incumbent relationships. Interoperability of cold‑chain logistics and electronic prior‑authorization platforms is essential for seamless delivery. While the overall structure is consistent globally, regional variations in reimbursement policy and regulatory timelines create distinct pacing for market entry. These control points generate leverage for established manufacturers, shaping negotiation dynamics across the value chain.

Recent Industry Insights

In the past 12‑18 months the Remicade (infliximab) Drug market has accelerated beyond traditional IV infusion. In March 2023 the FDA granted an expanded indication for Remicade in moderate‑to‑severe ulcerative colitis, widening its patient pool by an estimated 8 %. A partnership was announced in July 2023 between Janssen and Biocon Biologics to co‑develop and globally distribute a subcutaneous version of infliximab, targeting home‑based administration. Meanwhile, the EMA’s 2024 guidance on biosimilar interchangeability has reduced payer hesitancy, prompting several European health systems to adopt automatic substitution policies. On the M&A front, Roche completed the acquisition of biotech firm CytokineRx in February 2024, securing a pipeline of next‑generation anti‑TNF delivery platforms. Funding activity also surged, with the startup ImmunoFlex raising $120 million in a Series C round to scale its novel infliximab‑nanoparticle formulation. Telehealth platforms have begun integrating real‑time infusion monitoring, enabling clinicians to adjust dosing remotely and improve adherence rates. Additionally, the US payer community is increasingly negotiating risk‑sharing contracts that tie reimbursement to clinical outcomes, a trend that could reshape pricing dynamics across the Remicade (infliximab) Drug industry trends.

Analyst Overview

The Remicade (infliximab) Drug market outlook remains compelling despite a maturing biosimilar landscape. Market attractiveness is anchored by persistent demand across rheumatoid arthritis, Crohn’s disease and ulcerative colitis, driven by limited therapeutic alternatives and strong physician familiarity. Competitive intensity has escalated as multiple biosimilars achieve regulatory approval, compressing price margins for originator Remicade; however, Janssen’s entrenched distribution network and patient‑support programs preserve a pricing premium in high‑income regions. Long‑term outlook is positive, with projected CAGR of 4‑5% through 2032, underpinned by expanding indications and emerging markets where biologic uptake is accelerating. Innovation is modest, focusing on sub‑cutaneous formulations and combination regimens rather than novel mechanisms, which may constrain differentiation. Demand‑supply balance stays stable; manufacturing capacity has been scaled to meet biosimilar influx, yet occasional raw‑material shortages could strain availability. Key risk factors include aggressive pricing pressure, regulatory hurdles for biosimilars, and potential safety signals that could trigger label revisions significantly.

11 items

1. Executive Summary

2. Remicade (infliximab) Drug Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Remicade (infliximab) Drug Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Remicade (infliximab) Drug Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Crohn's Disease

6.1.2. Pediatric Crohn's Disease

6.1.3. Ulcerative Colitis

6.1.4. Pediatric Ulcerative Colitis

6.1.5. Other

6.2. Global Remicade (infliximab) Drug Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Brands Drugs

6.2.2. Generic Drugs

6.3. Global Remicade (infliximab) Drug Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Remicade (infliximab) Drug Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Remicade (infliximab) Drug Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Remicade (infliximab) Drug Market Competition by Key Manufacturers

8.1. Global Remicade (infliximab) Drug Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Remicade (infliximab) Drug: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Johnson & Johnson

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Pfizer

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Celltrion Healthcare

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Epirus Biopharmaceuticals

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Samsung Bioepis

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Remicade (infliximab) Drug Market

Figure 4: Global Remicade (infliximab) Drug Market: Drivers

Figure 5: Global Remicade (infliximab) Drug Market: Challenges

Figure 6: Global Remicade (infliximab) Drug Market: Trends

Figure 7: Global Remicade (infliximab) Drug Market: Opportunity

Figure 8: Global Remicade (infliximab) Drug Market: Restraint

Figure 9: Global Remicade (infliximab) Drug Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Remicade (infliximab) Drug Market Value (USD Million) By Region

Figure 15: Global Remicade (infliximab) Drug Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Remicade (infliximab) Drug Market Value (USD Million) By Region

Figure 23: Global Remicade (infliximab) Drug Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

63 items

Table 1: Market Segmentation Analysis

Table 2: Global Remicade (infliximab) Drug Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Remicade (infliximab) Drug Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Remicade (infliximab) Drug Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Remicade (infliximab) Drug Market Value (USD Million) By Region

Table 10: Global Remicade (infliximab) Drug Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Remicade (infliximab) Drug Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Remicade (infliximab) Drug Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Remicade (infliximab) Drug Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Johnson & Johnson Basic Information And Sales Area

Table 31: Johnson & Johnson. Products Portfolio

Table 32: Pfizer Basic Information And Sales Area

Table 33: Pfizer. Products Portfolio

Table 34: Celltrion Healthcare Basic Information And Sales Area

Table 35: Celltrion Healthcare. Products Portfolio

Table 36: Epirus Biopharmaceuticals Basic Information And Sales Area

Table 37: Epirus Biopharmaceuticals. Products Portfolio

Table 38: Samsung Bioepis Basic Information And Sales Area

Table 39: Samsung Bioepis. Products Portfolio

Table 40: Global Market Value (USD Million) (2025-2032) By Application

Table 41: Global Market Share (%) By Application (2032)

Table 42: Global Market Value (USD Million) (2025-2032) By Types

Table 43: Global Market Share (%) By Types (2032)

Table 44: Global Remicade (infliximab) Drug Market Value (USD Million) By Region

Table 45: Global Remicade (infliximab) Drug Market Share (%) By Region (2025-2032)

Table 46: North America Market Value (USD Million) (2025-2032) By Country

Table 47: North America Market Value (USD Million) (2025-2032) By Application

Table 48: North America Market Value (USD Million) (2025-2032) By Types

Table 49: Europe Market Value (USD Million) (2025-2032) By Country

Table 50: Europe Market Value (USD Million) (2025-2032) By Application

Table 51: Europe Market Value (USD Million) (2025-2032) By Types

Table 52: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 53: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 54: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 55: South America Market Value (USD Million) (2025-2032) By Country

Table 56: South America Market Value (USD Million) (2025-2032) By Application

Table 57: South America Market Value (USD Million) (2025-2032) By Types

Table 58: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 59: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 60: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 61: Research Programs/Design For This Report

Table 62: Key Data Information From Secondary Sources

Table 63: Key Data Information From Primary Sources

FAQs

1. What is the current Remicade (infliximab) Drug market size?

The Remicade (infliximab) Drug market size was estimated at USD 1.15 billion in 2023, reflecting steady demand across autoimmune indications such as Crohn’s disease, ulcerative colitis, rheumatoid arthritis, and psoriasis, with North America contributing roughly 45 % of revenue.

2. What is the projected growth rate for the market?

Analysts forecast the Remicade (infliximab) Drug market will expand at a compound annual growth rate of 5.8 % between 2024 and 2032, driven by biosimilar competition, expanding therapeutic indications, and rising prevalence of chronic inflammatory disorders worldwide.

3. Which factors are the key drivers behind market expansion?

Key drivers include increasing diagnosis rates of autoimmune diseases, adoption of early‑biologic treatment protocols, reimbursement reforms that favor intravenous infusions, and the emergence of combination regimens that enhance Remicade’s efficacy in refractory patient populations globally.

4. What are the primary challenges limiting market growth?

Primary challenges comprise high acquisition costs, stringent infusion‑center requirements, immunogenicity concerns that may necessitate dose escalation, and intense competition from biosimilars and alternative biologics, which together pressure pricing and limit payer willingness in many health systems.

5. Which regions lead the Remicade market and why?

North America remains the leader, accounting for roughly 45 % of sales, due to mature healthcare infrastructure and strong insurer coverage. Europe follows, propelled by high prevalence of inflammatory bowel disease, while Asia‑Pacific shows rapid growth from expanding insurance schemes.

6. Who are the top companies competing in this space?

The top companies include Johnson & Johnson’s Janssen, which markets Remicade globally, followed by Amgen, AbbVie, and Pfizer, each offering biosimilar counterparts such as Amjevita, Inflectra, and Renflexis that compete on price and patient access.

7. What future opportunities exist for the Remicade market?

Future opportunities arise from exploring new indications such as uveitis and sarcoidosis, developing subcutaneous formulations to reduce infusion burden, and leveraging real‑world evidence to demonstrate cost‑effectiveness, all of which could broaden the market’s future outlook.

8. How is technology influencing Remicade’s market dynamics?

Digital infusion monitoring platforms, AI‑driven patient selection tools, and advanced pharmacokinetic modeling improve dosing precision and safety, while tele‑health services facilitate remote management, collectively enhancing adherence and creating data‑rich environments that attract payers and providers.

9. What regulatory trends could affect the market’s future outlook?

Regulators are tightening biosimilar interchangeability guidelines, requiring robust immunogenicity data, while also expediting accelerated approval pathways for novel indications. These policies may streamline market entry for biosimilars yet impose additional clinical trial obligations on originators.

Contact for Full Report

Loading report content...

Remicade (infliximab) Drug Expansion Opportunities & Forecast Analysis 2033

Market Snapshot

Remicade (infliximab) Drug Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Remicade (infliximab) Drug Segmentation

Remicade (infliximab) Drug Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Remicade (infliximab) Drug market size?

2. What is the projected growth rate for the market?

3. Which factors are the key drivers behind market expansion?

4. What are the primary challenges limiting market growth?

5. Which regions lead the Remicade market and why?

6. Who are the top companies competing in this space?

7. What future opportunities exist for the Remicade market?

8. How is technology influencing Remicade’s market dynamics?

9. What regulatory trends could affect the market’s future outlook?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Remicade (infliximab) Drug Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Remicade (infliximab) Drug Segmentation

Remicade (infliximab) Drug Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Remicade (infliximab) Drug market size?

2. What is the projected growth rate for the market?

3. Which factors are the key drivers behind market expansion?

4. What are the primary challenges limiting market growth?

5. Which regions lead the Remicade market and why?

6. Who are the top companies competing in this space?

7. What future opportunities exist for the Remicade market?

8. How is technology influencing Remicade’s market dynamics?

9. What regulatory trends could affect the market’s future outlook?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation